Filing Details

Accession Number:
0001209191-23-020395
Form Type:
4
Zero Holdings:
No
Publication Time:
2023-03-21 19:15:04
Reporting Period:
2023-03-17
Accepted Time:
2023-03-21 19:15:04
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
1445283 Kineta Inc. KA Pharmaceutical Preparations (2834) 000000000
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1958184 Shawn Iadonato C/O Kineta, Inc.
219 Terry Ave. N., Suite 300
Seattle WA 98109
Chief Executive Officer Yes Yes No No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock Disposition 2023-03-17 1,536 $4.93 667,450 No 4 S Direct
Common Stock Disposition 2023-03-17 44 $5.23 667,406 No 4 S Direct
Common Stock Disposition 2023-03-20 1,119 $3.29 666,287 No 4 S Direct
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 S Direct
No 4 S Direct
No 4 S Direct
Reported Non-Derivative Holdings
Sec. Name Remaning Holdings Nature of Ownership Explanation
Common Stock 8,553 Indirect By IRA
Footnotes
  1. Shares of the Issuer's Common Stock were sold to satisfy tax obligations relating to the acquisition of shares of the Issuer's Common Stock in connection with the settlement of the vested portion of restricted stock units.
  2. The price reported in Column 4 is a weighted average price. The shares were purchased in multiple transactions at prices ranging from $4.22 to $5.18, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote.
  3. The price reported in Column 4 is a weighted average price. The shares were purchased in multiple transactions at prices ranging from $3.20 to $3.34, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote.